VEA
CPRX

Virtus ETF Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Virtus ETF Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Sell
8,137
-6,435
-44% -$190K 0.1% 237
2026
Q1 		$361K Hold
14,572
– – 0.17% 155
2025
Q4 		$340K Hold
14,572
– – 0.16% 157
2025
Q3 		$287K Sell
14,572
-8,232
-36% -$169K 0.16% 174
2025
Q2 		$495K Hold
22,804
– – 0.3% 95
2025
Q1 		$553K Buy
+22,804
New +$514K 0.36% 83

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus ETF Advisers's CPRX Position: Q2 2026 in Review

Virtus ETF Advisers reduced its Catalyst Pharmaceutical (CPRX) stake by 44% in Q2 2026, selling an estimated $190K and leaving 8,137 shares worth $256K. The position accounts for 0.1% of the portfolio, ranked #237.

Virtus ETF Advisers first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $553K in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Virtus ETF Advisers held 8,137 shares of Catalyst Pharmaceutical worth $256K as of Q2 2026.
  • Virtus ETF Advisers sold 6,435 Catalyst Pharmaceutical shares in Q2 2026, an estimated $190K.
  • Catalyst Pharmaceutical made up 0.1% of Virtus ETF Advisers's portfolio in Q2 2026, its #237 holding.
  • Virtus ETF Advisers first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Virtus ETF Advisers's Catalyst Pharmaceutical position peaked at $553K in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.